ストックスクリーナーアプリを入手
2.83
3.41%
-0.10
前日終値:
$2.93
開ける：
$2.95
24時間の取引高:
40,946
Relative Volume:
0.37
時価総額：
$17.88M
収益：
-
当期純損益:
$-11.46M
株価収益率:
-0.2021
EPS:
-14
ネットキャッシュフロー:
$-24.56M
1週間 パフォーマンス:
+8.43%
1か月 パフォーマンス:
+14.11%
6か月 パフォーマンス:
+9.69%
1年 パフォーマンス:
-75.39%
1日の値動き範囲:
$2.80
$2.9899
1週間の範囲:
$2.6101
$2.9899
52週間の値動き範囲:
$1.20
$17.75
Evaxion A S Adr Stock (EVAX) Company Profile
EVAX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EVAX
Evaxion A S Adr
|
2.83 | 17.88M | 0 | -11.46M | -24.56M | -14.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Evaxion A S Adr Stock (EVAX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-04-02 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2024-02-12 | 開始されました | H.C. Wainwright | Buy |
Evaxion A S Adr (EVAX) 最新ニュース
Short Interest in Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Expands By 148.8% - Defense World
Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments - Benzinga
Evaxion Boosts Equity through Debt Conversion, Improves Financial Flexibility - AInvest
Healthcare Stocks to Watch: Evaxion Biotech, CVRx, and Rockwell Medical Receive Bullish Sentiments - AInvest
Biotech Contrarians: Seizing Value in Europe's ADRs Amid Sectoral Slump - AInvest
European ADRs Dip As Evaxion And Grifols Climb - Finimize
European ADRs Dip While Biotech And Energy See Gains - Finimize
EVAX: Grant For Polio Vaccine Announced - Research Tree
Evaxion Biotech’s Earnings Call Highlights Progress and Challenges - MSN
Evaxion Biotech Reports Q1 2025 Progress and Financials - TipRanks
European ADRs Rise On S&P Europe Select Index - Finimize
Evaxion reports progress in cancer vaccine trial, extends cash runway - Investing.com
European Equities See Growth In US Trade - Finimize
80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - GlobeNewswire Inc.
Evaxion’s EVX-01 vaccine shows promising immune response in trial - Investing.com
European Equities Traded in the US as American Depositary Receipts Sharply Higher in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Drop in Monday Trading - TradingView
European Stocks Slip In US Trading With Mixed Performances - Finimize
Evaxion Biotech’s Optimistic Earnings Call Highlights - TipRanks
Evaxion Biotech Reports 2024 Financial Results and Strategic Progress - TipRanks
European Equities Traded in the US as American Depositary Receipts Tread Water in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading - TradingView
Evaxion Biotech stock plunges to 52-week low of $1.7 amid steep annual decline - Investing.com
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Tread Water in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading - TradingView
European Equities Traded in the US as ADRs Fall in Tuesday Trading - TradingView
Evaxion Biotech stock hits 52-week low at $1.79 amid market challenges - Investing.com
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week - TradingView
EVAX: Extended Trial is Excellent News - Research Tree
Evaxion Biotech A/SADR to Host Earnings Call - ACCESS Newswire
Evaxion Biotech stock hits 52-week low at $2.22 amid sharp decline - Investing.com
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading - TradingView
Evaxion Biotech A/S ADR (EVAX) Receives Upgrades Amid Sharp Decline – Is It Time for Investors to Reevaluate? - HPBL
Evaxion Biotech (EVAX) Stock Analysis: Price Decline, Analyst Ratings and Financial Ratios – market - HPBL
Evaxion secures Nasdaq listing with equity boost - Investing.com
European Equities Traded in the US as American Depositary Receipts Tread Water in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, End Week Up 3.2% - TradingView
Top investors say Evaxion Biotech A/S ADR (EVAX) ticks everything they need - SETE News
Evaxion Biotech A/S ADR [EVAX] Investment Guide: What You Need to Know - Knox Daily
Now Is The Time To Build A Position In Evaxion Biotech A/S ADR (NASDAQ:EVAX) - Marketing Sentinel
Evaxion A S Adr (EVAX) 財務データ
収益
当期純利益
現金流量
EPS
0.24%
3.39%
大文字化:
|
ボリューム (24 時間):